Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases

NCT07906145 is registered in ClinicalTrials.gov with Shanghai Qilu Pharmaceutical Research and Development Center LTD as lead sponsor.

NCT NCT07906145 Not yet recruiting Phase 1 76 participants (estimated) Started 2026

Follow this trial by email Email me the PDF

Get the NCT07906145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started December 2026. Interventional study, Phase 1, 76 participants (estimated). Lead sponsor Shanghai Qilu Pharmaceutical Research and Development Center LTD. Primary measure: Safety and Tolerability of QLS2416 Injection.

How it compares

39 similar trials: same condition (Sjogren's Syndrome) and phase

Enrollment

This trial
76
Middle half
12 to 36
Median
20
Trials with a value
39

Months from start to completion

This trial
36
Middle half
19.8 to 36.5
Median
31.9
Trials with a value
39

Sites

This trial
Not reported
Middle half
1 to 2
Median
1
Trials with a value
36
Posted results or a linked paper 18% 7 of 39 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
Official title
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of QLS2416 Injection in Participants With Autoimmune Diseases
Lead sponsor
Shanghai Qilu Pharmaceutical Research and Development Center LTD
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2029
Enrollment
76 (estimated)
Sites
Not reported

Conditions

MeSH condition names; the registry's own terms follow.

Arthritis, Rheumatoid, Autoimmune Diseases, Lupus Erythematosus, Systemic, Scleroderma, Systemic, Sjogren's Syndrome

Registry terms: primary sjögren's syndrome (pss), rheumatoid arthritis (ra), systemic lupus erythematosus, systemic sclerosis (ssc)

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Maximum age
70 Years
Healthy volunteers
No
Study type
Interventional
Lead sponsor
Shanghai Qilu Pharmaceutical Research and Development Center LTD

Arms

As registered; 1 arm.

Registered arms
Arm Type Interventions
QLS2416 Experimental QLS2416 Injection
Show registry wording

Dose Escalation Part: Participants with active SLE, RA, or pSS will receive single ascending subcutaneous doses of QLS2416 injection across 7 dose levels (0.025 mg to 6.0 mg).

Dose Expansion Part: Participants with active SLE or SSc will receive multiple dosing of QLS2416 injection at 3 dose levels within the 4-week treatment period.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Safety and Tolerability of QLS2416 Injection Up to 24 weeks
Show registry wording

Incidence and severity of treatment-emergent adverse events.

Lead sponsor's other trials

Shanghai Qilu Pharmaceutical Research and Development Center LTD, most recent start first.

Similar trials

Same condition (Sjogren's Syndrome) and phase, most recent start first.